6,746 Shares in Merck & Co., Inc. $MRK Bought by TritonPoint Partners LLC

TritonPoint Partners LLC bought a new position in shares of Merck & Co., Inc. (NYSE:MRK – Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 6,746 shares of the company’s stock, valued at approximately $716,000.

Several other institutional investors have also recently made changes to their positions in the business. Vanguard Group Inc. raised its holdings in shares of Merck & Co., Inc. by 0.9% during the fourth quarter. Vanguard Group Inc. now owns 254,322,763 shares of the company’s stock worth $26,770,014,000 after purchasing an additional 2,185,853 shares during the last quarter. State Street Corp raised its holdings in shares of Merck & Co., Inc. by 1.6% during the fourth quarter. State Street Corp now owns 120,040,168 shares of the company’s stock worth $12,737,504,000 after purchasing an additional 1,859,990 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Merck & Co., Inc. by 0.4% during the fourth quarter. Geode Capital Management LLC now owns 60,047,984 shares of the company’s stock worth $6,307,572,000 after purchasing an additional 249,110 shares during the last quarter. DLD Asset Management LP raised its holdings in shares of Merck & Co., Inc. by 30.1% during the third quarter. DLD Asset Management LP now owns 47,500,000 shares of the company’s stock worth $3,986,675,000 after purchasing an additional 11,000,000 shares during the last quarter. Finally, Morgan Stanley raised its holdings in shares of Merck & Co., Inc. by 0.8% during the fourth quarter. Morgan Stanley now owns 44,946,021 shares of the company’s stock worth $4,731,018,000 after purchasing an additional 359,486 shares during the last quarter. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Get Merck & Co. Inc. alerts:

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck Animal Health announced a definitive agreement to acquire TARGAN, a poultry biodevice company, which could strengthen Merck’s animal health division and broaden its technology-driven growth opportunities. Merck Animal Health to Acquire TARGAN
• Positive Sentiment: Merck saw unusually heavy call option buying, with traders purchasing 170,441 calls, a sharp jump versus normal volume that often signals bullish expectations from sophisticated investors.
• Positive Sentiment: Wells Fargo reiterated a buy rating on Merck, while another article highlighted that Wall Street’s overall bullish view continues to keep MRK on investors’ radar.
• Neutral Sentiment: Merck has also been featured in broader market commentary and “most searched” lists, suggesting rising attention rather than a new fundamental catalyst.
• Neutral Sentiment: One article noted Merck’s recent trading uptick but said it lagged the broader market, indicating modest price strength rather than a major breakout. Merck (MRK) Rises Yet Lags Behind Market: Some Facts Worth Knowing

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on MRK shares. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $142.00 price objective on shares of Merck & Co., Inc. in a report on Monday, March 30th. Zacks Research raised shares of Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 17th. Weiss Ratings cut shares of Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a report on Friday, May 15th. Barclays started coverage on shares of Merck & Co., Inc. in a report on Friday, February 20th. They issued an “overweight” rating and a $140.00 price objective for the company. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Merck & Co., Inc. from $125.00 to $135.00 and gave the company an “overweight” rating in a report on Monday, April 6th. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and seven have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Merck & Co., Inc. currently has a consensus rating of “Moderate Buy” and an average target price of $128.18.

Get Our Latest Report on Merck & Co., Inc.

Merck & Co., Inc. Stock Up 0.0%

MRK opened at $119.05 on Monday. Merck & Co., Inc. has a fifty-two week low of $76.66 and a fifty-two week high of $125.14. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30. The company has a fifty day moving average of $116.55 and a two-hundred day moving average of $113.32. The stock has a market capitalization of $294.04 billion, a price-to-earnings ratio of 33.54, a PEG ratio of 2.68 and a beta of 0.21.

Merck & Co., Inc. (NYSE:MRK – Get Free Report) last announced its earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.47) by $0.19. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The business had revenue of $16.29 billion for the quarter, compared to analyst estimates of $15.85 billion. During the same quarter last year, the business earned $2.22 earnings per share. The company’s revenue for the quarter was up 4.9% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, research analysts expect that Merck & Co., Inc. will post 5.17 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, July 8th. Stockholders of record on Monday, June 15th will be given a $0.85 dividend. The ex-dividend date is Monday, June 15th. This represents a $3.40 annualized dividend and a dividend yield of 2.9%. Merck & Co., Inc.’s dividend payout ratio (DPR) is 95.77%.

Merck & Co., Inc. Profile

(Free Report)

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

Featured Articles

• Five stocks we like better than Merck & Co., Inc.
• 3 ETFs Giving Ready-Made Access to the Discounted International Small-Cap Space
• What to Expect From Q2 Earnings as Tech Strength Broadens
• Viasat’s Orbiting Profits: Space Force Jackpot?
• Robinhood Wants a Bigger Role in IPOs—Here’s Why It Matters

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Free Report).

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.